SCHEMBL427478

SCHEMBL427478

CC1(C)COCN1C(=O)n1cnc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.44
ASAH1 Q13510 6/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.40
STAT6 P42226 1/20 0.40
DNMT3A Q9Y6K1 1/20 0.39
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425578 0.77 FAAH (0.47) HTTKMT2AALDH1A1HPGDHSD17B10
SCHEMBL427537 0.77 GABRA5 (0.38) HTTSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL427876 0.76 CNR2 (0.39) SMN1; SMN2ALDH1A1HPGDHSD17B10MAPT
SCHEMBL250172 0.75 HTT (0.66) HTTSMN1; SMN2ASAH1KMT2AMEN1
SCHEMBL7901045 0.72 CNR2 (0.37) SMN1; SMN2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL425743 0.70 FAAH (0.43) SMN1; SMN2ALDH1A1HPGDHSD17B10RAB9A
SCHEMBL427872 0.70 ALDH1A1 (0.36) SMN1; SMN2KMT2AALDH1A1HPGDHSD17B10
SCHEMBL425991 0.70 ALDH1A1 (0.40) SMN1; SMN2KMT2AALDH1A1HPGDHSD17B10
SCHEMBL427139 0.69 CNR2 (0.37) SMN1; SMN2KMT2AMEN1ALDH1A1HPGD
SCHEMBL424700 0.69 MGLL (0.47) SMN1; SMN2ASAH1ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 HTT 900/4885SMN1; SMN2 2818/4885ASAH1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.